

May 27, 2016

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Audited Financial Results & Recommendation of Final Dividend

Ref: Regulation 30 & 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 (hereinafter referred as Listing Regulations)

Dear Sir/Madam,

Please take note that the Board of Directors in their meeting held today i.e. May 27, 2016 approved the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Year ended March 31, 2016.

A copy of the Results along with Form A and the Auditor's Report issued by the Statutory Auditors M/s S. R. Batliboi & Co., LLP is attached herewith.

At the said meeting, the Board of Directors have also recommended a dividend of Rs. 2.45 per equity share (@ 24.5% on a face value of Rs. 10/- per share) for the year ended March 31, 2016. The dividend, if approved by the shareholders at the ensuing Annual General Meeting (AGM) will be paid on or after August 08, 2016.

Also, kindly take note that the Register of Members & Share Transfer books will remain closed from Friday, July 22, 2016 to Thursday, July 28, 2016 (both days inclusive) for the purpose of payment of dividend, if approved at the ensuing Annual General Meeting (AGM) scheduled to be held on July 28, 2016.

The Board Meeting commenced at 11:15 AM and concluded at 2:00 PM.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary & Legal Head

Encl: As above

FORM A


Pursuant to Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	Dr. Lal PathLabs Limited
2.	Annual financial statements for the year ended	Standalone financial statements for the year ended March 31, 2016
3.	Type of Audit observation	Un-qualified Report
4.	Frequency of observation	Not Applicable


For Dr. Lal PathLabs Limited



(Hony) Brig. Dr. Arvind Lal
Chairman & Managing Director

For S. R. Batliboi & Co., LLP
Chartered Accountants
ICAI Firm Registration Number: 301003E


Per Anil Gupta
(Partner)
Membership No. No. 87921

Date: May 27, 2016


Sunil Varma
Chairman of Audit Committee


Dilip Bidani
Chief Financial Officer

Date: May 27, 2016

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
Dr. Lal Pathlabs Limited

1. We have audited the standalone results of Dr. Lal Pathlabs Limited ('the Company') for the quarter ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The quarterly standalone financial results are the derived figures between the audited figures in respect of the year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The standalone financial results for the quarter ended March 31, 2016 and year to date ended March 31, 2016 have been prepared on the basis of the standalone financial results for the nine-month period ended December 31, 2015, the audited annual standalone financial statements as at and for the year ended March 31, 2016, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these standalone financial results based on our review of the standalone financial results for the nine-month period ended December 31, 2015 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual standalone financial statements as at and for the year ended March 31, 2016; and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
 - ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2016 and for the year ended March 31, 2016.

For S.R. BATLIBOI & CO. LLP

Chartered Accountants

ICAI Firm registration number: 301003E/ E300005

per Anil Gupta


Partner

Membership No.: 87921

Date: 27/3/2016

Place: New Delhi





Dr. Lal Path Labs Limited
Corporate Identity Number: L74899DL1995PLC065388
Regd. Office: Eskay House, 54, Hanuman Road, New Delhi - 110001
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Gurgaon - 122001
Website: www.lalpathlabs.com
Phone: +91 124 3016500 | Fax: +91 124 4234468
Email: cs@lalpathlabs.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2016

(Rs. in Lacs)						
S. No.	Particulars	3 Months Ended 31.03.2016	3 Months Ended 31.12.2015	Corresponding 3 months ended in the previous year 31.03.2015	Year Ended 31.03.2016	Previous Year Ended 31.03.2015
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		(Refer Note no. 2 below)		(Refer Note no. 2 below)		
1.	Income from Operations					
	(a) Net sales/Income from operations	19,129	18,201	16,639	76,534	63,658
	(b) Other Operating income	1	1	(1)	6	3
	Total Income from Operations (net)	19,130	18,202	16,638	76,540	63,661
2.	Expenses					
	(a) Cost of materials consumed	4,193	4,037	3,620	16,813	13,477
	(b) Employee benefits expense					
	i.) ESOP Cost	-	(2,738)	47	(347)	2,422
	ii.) ESPS Cost	(154)	349	137	435	137
	iii.) Others	3,291	3,495	2,668	13,218	10,562
	(c) Depreciation and amortization expense	813	839	863	3,201	3,184
	(d) Other Expenses					
	i.) Fees to collection centers	1,921	1,772	1,408	7,383	5,604
	ii.) Other Expenses	4,632	4,428	4,427	18,652	16,372
	Total Expenses	14,696	12,182	13,170	59,356	51,758
3.	Profit from operations before other income, finance costs and exceptional items (1-2)	4,434	6,020	3,468	17,184	11,903
4.	Other Income	616	521	418	2,041	1,264
5.	Profit from ordinary activities before finance costs, exceptional items (3 + 4)	5,050	6,541	3,886	19,225	13,167
6.	Finance Costs	28	3	36	49	39
7.i	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	5,022	6,538	3,850	19,176	13,128
7.ii	Profit from ordinary activities before tax (7.i + 2.b.i) (Before considering the ESOP cost)	5,022	3,800	3,897	18,829	15,550
8.	Exceptional Items	-	(1,663)	-	-	-
9.	Profit from ordinary activities before tax (7.i - 8)	5,022	8,201	3,850	19,176	13,128
10.	Tax Expense	1,775	2,205	1,315	6,600	4,353
11.	Net Profit from ordinary activities after tax (9 - 10)	3,247	5,996	2,535	12,576	8,775
12.i	Extraordinary items	-	-	-	-	-
12.ii	Profit for the year ended March 31st 2014 of the amalgamating companies pursuant to Scheme of Amalgamation (net of Tax)		-	-		401
13.	Net Profit for the period/year (11 - 12.i + 12.ii)	3,247	5,996	2,535	12,576	9,176
14.	Paid-up equity share capital (Face value of Rs. 10/- each)	8,268	8,264	5,463	8,268	5,463
15.	Paid-up preference share capital (Face value of Rs. 10/- each)	-	-	2,663	-	2,663
16.	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				39,584	23,797
17.i	Earning per share (before extraordinary items) (of Rs. 10/- each) (not annualised):					
	(a) Basic	3.93	7.26	4.65	15.31	16.07
	(b) Diluted	3.90	7.21	3.07	15.20	11.17
17.ii	Earning per share (after extraordinary items) (of Rs. 10/- each) (not annualised):					
	(a) Basic	3.93	7.26	4.65	15.31	16.07
	(b) Diluted	3.90	7.21	3.07	15.20	11.17

Statement of assets and liabilities


(Rs. in Lacs)

S. No.	PARTICULARS	As at	As at
		31.03.2016	31.03.2015
		(Audited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
a)	Share capital	8,268	8,126
b)	Reserves and surplus	39,584	23,797
	Sub-total - Shareholders' funds	47,851	31,923
2	Share application money pending allotment	73	-
3	Non-current liabilities		
a)	Trade payables	983	821
b)	Other long term liabilities	1,368	1,147
	Sub-total - Non current liabilities	2,351	1,968
4	Current liabilities		
a)	Trade payables	4,058	3,281
b)	Other current liabilities	1,741	5,845
c)	Short-term provisions	3,096	1,901
	Sub-total - Current liabilities	8,896	11,027
	TOTAL - EQUITY AND LIABILITIES	59,172	44,918
B	ASSETS		
1	Non-current assets		
a)	Fixed assets	13,388	11,997
b)	Non-current investments	1,159	1,144
c)	Deferred tax assets (net)	1,144	2,510
d)	Long-term loans and advances	1,554	1,359
e)	Other non-current assets	320	315
	Sub-total - Non-current assets	17,564	17,326
2	Current assets		
a)	Current investments	6,259	3,792
b)	Inventories	1,408	1,370
c)	Trade receivables	3,486	2,945
d)	Cash and bank balances	22,643	14,513
e)	Short-term loans and advances	7,151	4,526
f)	Other current assets	661	446
	Sub-total - Current assets	41,607	27,592
	TOTAL - ASSETS	59,172	44,918

Notes:

- The statutory auditors have performed the audit of financial results for the quarter and for the year ended March 31, 2016. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meetings held on May 26, 2016 & May 27, 2016 respectively.
- The figures for the last quarter of current and previous years are the balancing figures between the audited figures in respect of the full financial year and the published figures for nine months period ended for respective years.
- The Company has proposed final Dividend @ 24.50% (Rs. 2.45 per equity share having par value of Rs. 10), (net of Tax) for the financial year 2015-16 aggregating to Rs. 2,440 Lacs including dividend tax.
- Tax expenses are inclusive of/net off deferred tax charge/credit and tax adjustment for earlier years.
- As the Company is engaged in a single primary business segment, the disclosure requirement of Accounting Standard (AS 17) 'Segment Reporting' notified under Section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013 are not applicable.
- Previous year/period figures have been regrouped wherever considered necessary.

For and on behalf of the Board of Directors of Dr. Lal PathLabs Limited


 (Hon'y) Brig. Dr. Arvind Lal
 (Chairman & Managing Director)


 Place : New Delhi
 Date : 27th May 2016

FORM A

Pursuant to Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	Dr. Lal PathLabs Limited
2.	Annual financial statements for the year ended	Consolidated financial statements for the year ended March 31, 2016
3.	Type of Audit observation	Un-qualified Report
4.	Frequency of observation	Not Applicable


For Dr. Lal PathLabs Limited



(Hony) Brig. Dr. Arvind Lal
Chairman & Managing Director


For S. R. Batliboi & Co., LLP
Chartered Accountants

ICAI Firm Registration Number: 301003E




Per Anil Gupta
(Partner)
Membership No. No. 87921

Date: May 27, 2016



Sunil Varma
Chairman of Audit Committee



Dilip Bidani
Chief Financial Officer

Date: May 27, 2016

Auditor's Report On Quarterly Consolidated Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
Dr. Lal Pathlabs Limited,

1. We have audited the consolidated financial results of Dr. Lal Pathlabs Limited ('the Company') for the quarter ended March 31, 2016 and the consolidated financial results for the year ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The quarterly consolidated financial results are the derived figures between the audited figures in respect of the year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The consolidated financial results for the quarter and year to date ended March 31, 2016 have been prepared on the basis of the consolidated financial results for the nine-month period ended December 31, 2015, the audited annual consolidated financial statements as at and for the year ended March 31, 2016, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these consolidated financial results based on our review of the consolidated financial results for the nine-month period ended December 31, 2015 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 "Interim Financial Reporting", Interim Financial Reporting, specified under the Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual consolidated financial statements as at and for the year ended March 31, 2016; and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. We did not audit the financial statements and other financial information of 1 subsidiary included in the consolidated quarterly financial results and consolidated year to date results, whose financial statements reflect total assets of Rs.21,816,448 as at March 31, 2016, total revenues and loss after tax of Rs.37,373,774 and Rs.3,68,558 respectively for the year then ended, included in the accompanying consolidated financial statements in respect of a subsidiary. The financial statements and other financial information of that subsidiary have been audited by other auditor whose reports have been furnished to us, and our conclusion on the quarterly financial results is based solely on the reports of the other auditor.
4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly consolidated financial results as well as the year to date results:
 - a. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in this regard; and



S.R. BATLIBOI & CO. LLP

Chartered Accountants

- b. give a true and fair view of the consolidated net profit and other financial information for the consolidated quarter ended March 31, 2016 and for the year ended March 31, 2016.

For S.R. Batliboi & CO. LLP

Chartered Accountants

ICAI Firm Registration Number: 301003E/E300005

Anil Gupta

per Anil Gupta

Partner

Membership Number: 87921

Place:

New Delhi

Date:

27/7/2016





Dr. Lal Path Labs Limited
Corporate Identity Number: L74899DL1995PLC065388
Regd. Office: Eskay House, 54, Hanuman Road, New Delhi – 110001
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Gurgaon - 122001
Website: www.lalpathlabs.com
Phone: +91 124 3016500 | Fax: +91 124 4234468
Email: cs@lalpathlabs.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2016

(Rs. in Lacs)

S. No.	Particulars	3 Months Ended 31.03.2016	3 Months Ended 31.12.2015	Corresponding 3 months ended in the previous year 31.03.2015	Year Ended 31.03.2016	Previous Year Ended 31.03.2015
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		(Refer note no. 2 below)		(Refer note no. 2 below)		
1.	Income from Operations					
	(a) Net sales/Income from operations	19,770	18,856	17,184	79,126	65,956
	(b) Other Operating income	1	1	-	6	3
	Total Income from Operations (net)	19,771	18,857	17,184	79,132	65,959
2.	Expenses					
	(a) Cost of materials consumed	4,316	4,165	3,724	17,292	13,916
	(b) Employee benefits expense					
	i.) ESOP Cost	-	(2,738)	47	(347)	2,422
	ii.) ESPS Cost	(154)	349	137	435	137
	iii.) Others	3,394	3,586	2,756	13,595	10,880
	(c) Depreciation and amortization expense	726	743	789	2,828	2,819
	(d) Other Expenses					
	i.) Fees to collection centers	1,922	1,772	1,420	7,388	5,609
	ii.) Other Expenses	4,879	4,717	4,722	19,796	17,400
	Total Expenses	15,084	12,594	13,595	60,988	53,183
3.	Profit from operations before other income, finance costs and exceptional items (1-2)	4,687	6,263	3,589	18,144	12,776
4.	Other Income	617	442	352	1,977	1,236
5.	Profit from ordinary activities before finance costs, exceptional items (3 + 4)	5,305	6,705	3,941	20,121	14,012
6.	Finance Costs	27	5	37	50	40
7.i	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	5,278	6,700	3,904	20,072	13,972
7.ii	Profit from ordinary activities before tax (7.i +2.b.i) (Before considering the ESOP cost)	5,278	3,962	3,951	19,725	16,394
8.	Exceptional Items	-	(1,663)	-	-	-
9	Profit from ordinary activities before tax (7.i - 8)	5,278	8,363	3,904	20,072	13,972
10.	Tax Expense	1,813	2,252	1,028	6,749	4,328
11.	Net Profit from ordinary activities after tax (9 - 10)	3,465	6,111	2,876	13,323	9,644
12.	Extraordinary items	-	-	-	-	-
13.	Net Profit for the period/year (11 - 12)	3,465	6,111	2,876	13,323	9,644
14.	Minority Interest	21	29	1	104	75
15.	Net Profit after taxes and minority interest (13 - 14)	3,444	6,082	2,875	13,219	9,569
16.	Paid-up equity share capital (Face value of Rs. 10/- each)	8,268	8,264	5,463	8,268	5,463
17.	Paid-up preference share capital (Face value of Rs. 10/- each)	-	-	2,663	-	2,663
18.	Reserves excluding Revaluation Reserves as per balance sheet	-	-	-	42,394	25,982
19.i	Earning per share (before extraordinary items) (of Rs. 10/- each) (not annualised):					
	(a) Basic	4.17	7.37	5.28	16.09	16.79
	(b) Diluted	4.14	7.31	3.48	15.98	11.65
19.ii	Earning per share (after extraordinary items) (of Rs. 10/- each) (not annualised):					
	(a) Basic	4.17	7.37	5.28	16.09	16.79
	(b) Diluted	4.14	7.31	3.48	15.98	11.65

Statement of assets and liabilities

(Rs. in Lacs)


Sl. No.	PARTICULARS	As at	As at
		31.03.2016 (Audited)	31.03.2015 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
a)	Share capital	8,268	8,126
b)	Reserves and surplus	42,394	25,982
	Sub-total - Shareholders' funds	50,662	34,108
2	Share application money pending allotment	73	-
3	Minority interest	289	230
4	Non-current liabilities		
a)	Trade payables	1,023	843
b)	Other long term liabilities	1,378	1,154
c)	Long-term provisions	20	21
	Sub-total - Non current liabilities	2,421	2,018
5	Current liabilities		
a)	Trade payables	4,227	3,416
b)	Other current liabilities	1,755	5,859
c)	Short-term provisions	3,097	1,902
	Sub-total - Current liabilities	9,078	11,176
	TOTAL - EQUITY AND LIABILITIES	62,523	47,531
B	ASSETS		
1	Non-current assets		
a)	Fixed assets	16,973	15,103
b)	Deferred tax assets (net)	1,205	2,540
c)	Long-term loans and advances	1,591	1,394
d)	Other non-current assets	381	327
	Sub-total - Non-current assets	20,150	19,364
2	Current assets		
a)	Current investments	6,432	3,792
b)	Inventories	1,452	1,428
c)	Trade receivables	3,631	3,096
d)	Cash and bank balances	22,964	14,819
e)	Short-term loans and advances	7,230	4,571
f)	Other current assets	665	462
	Sub-total - Current assets	42,374	28,167
	TOTAL - ASSETS	62,523	47,531

Notes:

- The statutory auditors have performed the audit of financial results for the quarter and for the year ended March 31, 2016. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on May 26, 2016 & May 27, 2016.
- The figures for the last quarter of current and previous years are the balancing figures between the audited figures in respect of the full financial year and the published figures for nine months period ended for respective years.
- The Consolidated Financial Results represents consolidated results of the Company and its subsidiaries.
- The Company has proposed final Dividend @ 24.50% (Rs. 2.45 per equity share having par value of Rs. 10), (net of Tax) for the financial year 2015-16 aggregating to Rs. 2,440 Lacs including dividend tax.
- Tax expenses are inclusive of/net off deferred tax charge/credit and tax adjustment for earlier years.
- As the group's business is engaged in a single primary business segment, the disclosure requirement of Accounting Standard (AS 17) 'Segment Reporting' notified under Section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013 are not applicable.
- Previous year/period figures have been regrouped wherever considered necessary.

For and on behalf of the Board of Directors of Dr. Lal Path Labs Limited

Place: New Delhi
Date: 27th May 2016


(Hon'y) Brig. Dr. Arvind Lal
(Chairman & Managing Director)